Pharmacy Updates

Erythropoiesis Stimulating Agents (ESA) Risk Evaluation and Mitigation Strategy (REMS)

Effective February 16, 2011 Erythropoiesis Stimulating Agents (ESA) must be prescribed and used in accordance to the FDA-mandated risk management program, known as the Risk Evaluation and Mitigation Strategy (REMS).

Goals of the REMS for ESAs are:

To assist patients and clinicians in making informed decisions on the use of ESAs; and
To mitigate the risk of increased mortality and poorer tumor outcome in patients with cancer.

Requirements are:

  • All patients receiving ESAs (Epogen, Procrit, Aranesp) must be provided a Medication Guide

For patients with Cancer, in addition to providing medication guide:

  • Hospital Certification: Hospital providing ESA must receive ESA APPRISE Oncology Certification.
  • Healthcare provider (HCP) Enrollment: Clinicians prescribing ESAs in patients with cancer must enroll in the ESA APPRISE Oncology Program.
  • Acknowledgment Form: certified HCP and patient documentation of Risk vs. Benefit discussion must be maintained.

If you need any further assistance, please contact pharmacy at extension 64696.

Latest News

View All